High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1–6 patients without cirrhosis

Massimo Puoti, Graham R. Foster, Stanley Wang, David Mutimer, Edward Gane, Christophe Moreno, Ting Tsung Chang, Samuel S. Lee, Rui Marinho, Jean Francois Dufour, Stanislas Pol, Christophe Hezode, Stuart C. Gordon, Simone I. Strasser, Paul J. Thuluvath, Zhenzhen Zhang, Sandra Lovell, Tami Pilot-Matias, Federico J. Mensa

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Background & Aims: Glecaprevir plus pibrentasvir (G/P) is a pangenotypic, once-daily, ribavirin-free direct-acting antiviral (DAA) treatment for hepatitis C virus (HCV) infection. In nine phase II or III clinical trials, G/P therapy achieved rates of sustained virologic response 12 weeks after treatment (SVR12) of 93–100% across all six major HCV genotypes (GTs). An integrated efficacy analysis of 8- and 12-week G/P therapy in patients without cirrhosis with HCV GT 1–6 infection was performed. Methods: Data were pooled from nine phase II and III trials including patients with chronic HCV GT 1–6 infection without cirrhosis who received G/P (300 mg/120 mg) for either 8 or 12 weeks. Patients were treatment naïve or treatment experienced with peginterferon, ribavirin, and/or sofosbuvir; all patients infected with HCV GT 3 were treatment naïve. Efficacy was evaluated as the SVR12 rate. Results: The analysis included 2,041 patients without cirrhosis. In the intent-to-treat population, 943/965 patients (98%) achieved SVR12 when treated for eight weeks, and 1,060/1,076 patients (99%) achieved SVR12 when treated for 12 weeks; the difference in rates was not significant (p = 0.2). A subgroup analysis demonstrated SVR12 rates > 95% across baseline factors traditionally associated with lower efficacy. G/P was well tolerated, with one DAA-related serious adverse event (<0.1%); grade 3 laboratory abnormalities were rare. Conclusions: G/P therapy for eight weeks in patients with chronic HCV GT 1–6 infection without cirrhosis achieved an overall SVR12 rate of 98% irrespective of baseline patient or viral characteristics; four additional weeks of treatment did not significantly increase the SVR12 rate, demonstrating that the optimal treatment duration in this population is eight weeks. Lay summary: In this integrated analysis of nine clinical trials, patients with chronic HCV genotype 1–6 infection without cirrhosis were treated for either 8 or 12 weeks with the direct-acting antiviral regimen glecaprevir/pibrentasvir (G/P). The cure rate was 98% and 99% following 8 and 12 weeks of treatment, respectively; the difference in rates was not significant (p = 0.2), nor was there a significant difference in the cure rates across the two treatment durations on the basis of baseline patient or viral characteristics. These results, along with a favourable safety profile, indicate that G/P is a highly efficacious and well-tolerated pangenotypic eight-week therapy for most patients with chronic HCV infection.

Original languageEnglish
Pages (from-to)293-300
Number of pages8
JournalJournal of Hepatology
Volume69
Issue number2
DOIs
Publication statusPublished - 2018 Aug

All Science Journal Classification (ASJC) codes

  • Hepatology

Fingerprint Dive into the research topics of 'High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1–6 patients without cirrhosis'. Together they form a unique fingerprint.

  • Cite this

    Puoti, M., Foster, G. R., Wang, S., Mutimer, D., Gane, E., Moreno, C., Chang, T. T., Lee, S. S., Marinho, R., Dufour, J. F., Pol, S., Hezode, C., Gordon, S. C., Strasser, S. I., Thuluvath, P. J., Zhang, Z., Lovell, S., Pilot-Matias, T., & Mensa, F. J. (2018). High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1–6 patients without cirrhosis. Journal of Hepatology, 69(2), 293-300. https://doi.org/10.1016/j.jhep.2018.03.007